This past spring at EASL, Astex Pharma $ASTX introduced their preclinical, fragment-based drug candidate AT26893 for Hepatitis C virus (HCV) infection. ASTX has two more abstracts accepted for presentation at AASLD in November 2012 - see full details below.
0 Comments
Continue reading below for a round-up of 2q-2012 earnings commentary from Momenta Pharma's $MNTA partners and competitors, as well as about biosimilars in general. Includes Sanofi $SNY, Mylan $MYL, Watson Pharma $WPI, Pfizer $PFE, and Teva Pharma $TEVA:
It is still a work in progress, but please visit and provide feedback on the brand new Sarepta Therapeutics $SRPT stock research page. SRPT has of course been prominently in the news as they have released promising data for eteplirsen, their antisense drug for Duchenne muscular dystrophy (DMD). You'll find a collection of articles analyzing the data and the stock, basic information presented by the company recently, scientific and medical conference presentations, etc. In other words, all of the due diligence resources you've come to expect from BiotechDueDiligence.
DIFICID (fidaxomycin) was launched about a year ago for C. dfficile infections by Optimer Pharma $OPTR with support from Cubist Pharma $CBST. Continue reading for the latest updates on this program from the two companies, as well as comments on CBST's additional C. difficle (CDAD) prodcut CB-315.
A quiet quarter on the partner front for ISIS news. See below for the details:
Sanofi $SNY - only mentioned KYNAMRO (mipomersen) in passing...still awaiting US and EU regulatory decisions and FDA advisory committee vote in October 2012. Biogen $BIIB (transcript via Morningstar) "Through a second collaboration with Isis Pharmaceuticals, we added an interesting preclinical program intended to develop and commercialize the treatment for myotonic dystrophy. This program fits squarely within our strategy to focus on highly differentiated therapies for serious, unmet needs in neurology." "As George mentioned, we recently added a promising preclinical program targeting myotonic dystrophy or DM1 through a second collaboration with Isis. DM1 is a debilitating neuromuscular disease that affects about 150,000 people in the U.S., Europe and Japan. It's caused by a genetic defect in the dystrophia myotonica-protein kinase or DMPK gene and there are currently no disease modifying therapies to treat DM1." "As discussed during our Analyst Day one of our focus areas within neurology is genetically well-defined diseases. DM1 fits squarely within that particular approach. The disease is caused by the accumulation of toxic RNAs in the nucleus of affected individuals, because of CTG repeats and the Isis molecule is designed to specifically correct this accumulation. Isis is working to discover the lead drug candidate for the program, which we hope to take in the Phase I next year." |
Categories
All
Archives
January 2020
|